




OneCellDiagnostics

OncoMonitor

Longitudinal Monitoring Test

OncoMonitor

A Novel Liquid Biopsy Test for Long-term Disease Monitoring & Minimal Residual Disease Detection for Cancer Management



Assess Disease Dynamics over time, and gain disease & treatment insights which helps in timely intervention & informed decision-making for Clinicians.

Introduction

Minimal residual disease or MRD is a condition where the disease is present in the patient but in low detectable levels. This means that detecting them by traditional detection methods like radiological imaging may be challenging. Recent developments on liquid biopsy are a huge step forward paving way for detecting minimal residual disease promptly. This enables patient monitoring at an early stage of recurrence or relapse.

In comparison to metastatic tumors, early-stage diseases have lower tumor burden which may be challenging to be detected in patient's blood or an imaging technique. Thus, the evaluation of MRD from blood is challenging and requires highly sensitive detection techniques.

Both circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) are emerging to be vital resources to monitor MRD in cancer patients. For instance, a high ctDNA load in patients is usually associated with worse outcomes in advanced cancers. ctDNA-based MRD detection may also unveil the molecular evolution of residual tumor cells in real-time during its progression, thereby eliminating or aiding in the early detection of metastatic recurrence. Similarly, the presence of CTC upon enumeration is associated with recurring disease, disease relapse, or metastatic disease. Especially, the clinical utility


of CTCs in monitoring treatment response and prognostication has been demonstrated for various metastatic cancers. Due to its improved utility, several technological advancements are fast emerging to isolate and enrich CTCs including microfluidics and hydrodynamic centrifugal forces. These allow fast and efficient size-based isolation of viable CTCs.

The test also offers genetic counseling designed based on individual outcomes to assist in understanding. With test outcomes, patients have the benefit of being closely monitored to enable prompt interventions without delays.

OncoMonitor® Reporting - Harnessing the Power of AI and ML for Precision Oncology

OncoMonitor® test comes with a cutting-edge reporting solution that combines the power of artificial intelligence (AI) and machine learning (ML) along with the expertise of oncologists. By providing clear, actionable genomic findings and a secure, data-driven platform for collaboration and decision-making.

The OncoMonitor® report is a powerful tool for oncologists, providing clear, unambiguous, and actionable genomic findings that are essential for developing patient-specific treatment plans. The report provides a detailed description of patient-specific genetic mutations and pathways in



accordance with international guidelines and is based on highly reliable and internally curated knowledge databases (ikb).

At the heart of the OncoMonitor® report is iCARE™, the virtual genomic lab of oncologists.

AI-powered precision monitoring iCARE™

console is a virtual genomic lab designed by the oncologists for the oncologists.

iCARE™ allows doctors to visualize genomic variants in real-time, access high-level interactive genomic reporting, and leverage a rich database of reference literature.




Table 1. Important features of OncoMonitor®

No.	Features	Detected in OncoMonitor®
1	Genomic alterations	1000 targets of clinically actionable genes • SNVs and INDELs • Copy number variations • Translocations (Fusions)
2	Immuno-oncology markers	MSI by NGS
3	PD-L1	PD-L1 by immunofluorescence on OncoDiscover®-CTC
4	Mean sequencing depth	5000X
5	Turnaround time (TAT)	10-12 working days
6	Indications	Solid tumors
7	Sample collection	Peripheral blood
8	On target coverage	>99%
9	Approval	CTC detection by OncoDiscover® technology – approved by DCGI

Benefits of OncoMonitor®

- OncoMonitor® allows Longitudinal Monitoring via regular assessment of CTC numbers and ctDNA load providing insights to potential disease relapse and treatment response.
- OncoMonitor® adds prognostic value by predicting disease relapse, progression, and overall survival, aiding informed decision-making for both patients and healthcare providers.
- Provides a swift real-time report on OncoDiscover® CTC, ctDNA load, and relevant mutations.

Conclusion

Overall, OncoMonitor® detects MRD effectively by combining ctDNA and CTCs. With its high sensitivity and specificity, the test can detect variants at a high sequencing depth with an on-target coverage of >99%. Identifying MRD is important in cancer patients after an interventional process, especially with the limitations in conventional techniques. Due to this, more validations on ctDNA and CTC are essential for faster clinical utility. This combinatorial

approach with both ctDNA and CTC may be transforming MRD with its reliable and reproducible predictions of residual disease.

References

1. Davis, A.A. and Cristofanilli, M., 2020. Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?. *JAMA oncology*, 6(9), pp.1332-1333.
2. Ko, J.M.Y., Vardhanabhuti, V., Ng, W.T., Lam, K.O., Ngan, R.K.C., Kwong, D.L.W., Lee, V.H.F., Lui, Y.H., Yau, C.C., Kwan, C.K. and Li, W.S., 2020. Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. *British Journal of Cancer*, 123(1), pp.114-125.
3. Chen, H. and Zhou, Q., 2023. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease. *Oncology Reports*, 49(5), pp.1-13.



About OneCell Diagnostics

OneCell Diagnostics is on a mission to democratize precision cancer monitoring and testing to make cancer testing an Actionable, Accessible, and Affordable solution. We bring the power of Genomics data and Artificial Intelligence (AI) to healthcare. We intend to impact millions of cancer patients' lives by providing high-quality precision therapy options to all needful patients worldwide.

US Office:

20380 Town Center Lane,
#218 Cupertino, CA 95014
United States

Mumbai Office:

404, Alpha Building, Main Street,
Hirandani Gardens, Powai,
Mumbai 400076, India

Pune Lab:

B 209, Go Square,
Aundh-Hinjewadi Road, Wakad,
Pune 411057, India